PD-L1 and durvalumab after chemoradiation for stage III NSCLC in Netherlands Cancer Registry

Stephen Liu shared on X about a recent paper by Damhuis Ram et al. titled “Association between PD-L1 score and the outcomes of consolidation durvalumab in a large nationwide series of patients with stage III NSCLC treated with chemoradiotherapy” published in Clinical Lung Cancer.

Authors: Damhuis Ram, Idris Bahce, Suresh Senan.

“PD-L1 and outcomes from consolidation durvalumab after chemoradiation for stage III NSCLC in Netherlands Cancer Registry at Clinical Lung Cancer.

From 2017 to 2021, use of PACIFIC increased from 2% to 62%. 4y OS 67% for PDL1 high, 46% for low, 51% for negative.”

Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.